Report Thumbnail
Product Code LP0913910483JL4
Published Date 2024/2/14
English131 PagesGlobal

Global Cystic Fibrosis Therapeutics Market Growth (Status and Outlook) 2024-2030Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code LP0913910483JL4◆The Feb 2026 edition is also likely available. We will check with the publisher immediately.
Published Date 2024/2/14
English 131 PagesGlobal

Global Cystic Fibrosis Therapeutics Market Growth (Status and Outlook) 2024-2030Pharmaceutical_LifeSciense Market



Abstract


Summary

According to our LPI (LP Information) latest study, the global Cystic Fibrosis Therapeutics market size was valued at US$ 4950.4 million in 2023. With growing demand in downstream market, the Cystic Fibrosis Therapeutics is forecast to a readjusted size of US$ 12390 million by 2030 with a CAGR of 14.0% during review period.
The research report highlights the growth potential of the global Cystic Fibrosis Therapeutics market. Cystic Fibrosis Therapeutics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Cystic Fibrosis Therapeutics. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Cystic Fibrosis Therapeutics market.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Cystic Fibrosis Therapeutics market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Cystic Fibrosis Therapeutics market. It may include historical data, market segmentation by Type (e.g., CFTR, Mucolytics), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Cystic Fibrosis Therapeutics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Cystic Fibrosis Therapeutics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Cystic Fibrosis Therapeutics industry. This include advancements in Cystic Fibrosis Therapeutics technology, Cystic Fibrosis Therapeutics new entrants, Cystic Fibrosis Therapeutics new investment, and other innovations that are shaping the future of Cystic Fibrosis Therapeutics.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Cystic Fibrosis Therapeutics market. It includes factors influencing customer ' purchasing decisions, preferences for Cystic Fibrosis Therapeutics product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Cystic Fibrosis Therapeutics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Cystic Fibrosis Therapeutics market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Cystic Fibrosis Therapeutics market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Cystic Fibrosis Therapeutics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Cystic Fibrosis Therapeutics market.
Market Segmentation:
Cystic Fibrosis Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
CFTR
Mucolytics
PERT
Anti-infectives
Bronchodilators
Segmentation by application
Hospitals
Clinics
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Vertex Pharmaceuticals
F. Hoffmann-La Roche
AbbVie
Gilead Sciences
Novartis
AstraZeneca
Bayer
Celtaxsys
Pharmaxis
ProQR Therapeutics
PTC Therapeutics
Alcresta Therapeutics
Insmed Incorporated
Savara
Cyclacel Pharmaceuticals
Vectura
Allergan

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats
  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global Cystic Fibrosis Therapeutics Market Size 2019-2030
      • 2.1.2 Cystic Fibrosis Therapeutics Market Size CAGR by Region 2019 VS 2023 VS 2030
    • 2.2 Cystic Fibrosis Therapeutics Segment by Type
      • 2.2.1 CFTR
      • 2.2.2 Mucolytics
      • 2.2.3 PERT
      • 2.2.4 Anti-infectives
      • 2.2.5 Bronchodilators
    • 2.3 Cystic Fibrosis Therapeutics Market Size by Type
      • 2.3.1 Cystic Fibrosis Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030)
      • 2.3.2 Global Cystic Fibrosis Therapeutics Market Size Market Share by Type (2019-2024)
    • 2.4 Cystic Fibrosis Therapeutics Segment by Application
      • 2.4.1 Hospitals
      • 2.4.2 Clinics
    • 2.5 Cystic Fibrosis Therapeutics Market Size by Application
      • 2.5.1 Cystic Fibrosis Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030)
      • 2.5.2 Global Cystic Fibrosis Therapeutics Market Size Market Share by Application (2019-2024)
  • 3 Cystic Fibrosis Therapeutics Market Size by Player

    • 3.1 Cystic Fibrosis Therapeutics Market Size Market Share by Players
      • 3.1.1 Global Cystic Fibrosis Therapeutics Revenue by Players (2019-2024)
      • 3.1.2 Global Cystic Fibrosis Therapeutics Revenue Market Share by Players (2019-2024)
    • 3.2 Global Cystic Fibrosis Therapeutics Key Players Head office and Products Offered
    • 3.3 Market Concentration Rate Analysis
      • 3.3.1 Competition Landscape Analysis
      • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
    • 3.4 New Products and Potential Entrants
    • 3.5 Mergers & Acquisitions, Expansion
  • 4 Cystic Fibrosis Therapeutics by Regions

    • 4.1 Cystic Fibrosis Therapeutics Market Size by Regions (2019-2024)
    • 4.2 Americas Cystic Fibrosis Therapeutics Market Size Growth (2019-2024)
    • 4.3 APAC Cystic Fibrosis Therapeutics Market Size Growth (2019-2024)
    • 4.4 Europe Cystic Fibrosis Therapeutics Market Size Growth (2019-2024)
    • 4.5 Middle East & Africa Cystic Fibrosis Therapeutics Market Size Growth (2019-2024)
  • 5 Americas

    • 5.1 Americas Cystic Fibrosis Therapeutics Market Size by Country (2019-2024)
    • 5.2 Americas Cystic Fibrosis Therapeutics Market Size by Type (2019-2024)
    • 5.3 Americas Cystic Fibrosis Therapeutics Market Size by Application (2019-2024)
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil
  • 6 APAC

    • 6.1 APAC Cystic Fibrosis Therapeutics Market Size by Region (2019-2024)
    • 6.2 APAC Cystic Fibrosis Therapeutics Market Size by Type (2019-2024)
    • 6.3 APAC Cystic Fibrosis Therapeutics Market Size by Application (2019-2024)
    • 6.4 China
    • 6.5 Japan
    • 6.6 Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia
  • 7 Europe

    • 7.1 Europe Cystic Fibrosis Therapeutics by Country (2019-2024)
    • 7.2 Europe Cystic Fibrosis Therapeutics Market Size by Type (2019-2024)
    • 7.3 Europe Cystic Fibrosis Therapeutics Market Size by Application (2019-2024)
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia
  • 8 Middle East & Africa

    • 8.1 Middle East & Africa Cystic Fibrosis Therapeutics by Region (2019-2024)
    • 8.2 Middle East & Africa Cystic Fibrosis Therapeutics Market Size by Type (2019-2024)
    • 8.3 Middle East & Africa Cystic Fibrosis Therapeutics Market Size by Application (2019-2024)
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends
  • 10 Global Cystic Fibrosis Therapeutics Market Forecast

    • 10.1 Global Cystic Fibrosis Therapeutics Forecast by Regions (2025-2030)
      • 10.1.1 Global Cystic Fibrosis Therapeutics Forecast by Regions (2025-2030)
      • 10.1.2 Americas Cystic Fibrosis Therapeutics Forecast
      • 10.1.3 APAC Cystic Fibrosis Therapeutics Forecast
      • 10.1.4 Europe Cystic Fibrosis Therapeutics Forecast
      • 10.1.5 Middle East & Africa Cystic Fibrosis Therapeutics Forecast
    • 10.2 Americas Cystic Fibrosis Therapeutics Forecast by Country (2025-2030)
      • 10.2.1 United States Cystic Fibrosis Therapeutics Market Forecast
      • 10.2.2 Canada Cystic Fibrosis Therapeutics Market Forecast
      • 10.2.3 Mexico Cystic Fibrosis Therapeutics Market Forecast
      • 10.2.4 Brazil Cystic Fibrosis Therapeutics Market Forecast
    • 10.3 APAC Cystic Fibrosis Therapeutics Forecast by Region (2025-2030)
      • 10.3.1 China Cystic Fibrosis Therapeutics Market Forecast
      • 10.3.2 Japan Cystic Fibrosis Therapeutics Market Forecast
      • 10.3.3 Korea Cystic Fibrosis Therapeutics Market Forecast
      • 10.3.4 Southeast Asia Cystic Fibrosis Therapeutics Market Forecast
      • 10.3.5 India Cystic Fibrosis Therapeutics Market Forecast
      • 10.3.6 Australia Cystic Fibrosis Therapeutics Market Forecast
    • 10.4 Europe Cystic Fibrosis Therapeutics Forecast by Country (2025-2030)
      • 10.4.1 Germany Cystic Fibrosis Therapeutics Market Forecast
      • 10.4.2 France Cystic Fibrosis Therapeutics Market Forecast
      • 10.4.3 UK Cystic Fibrosis Therapeutics Market Forecast
      • 10.4.4 Italy Cystic Fibrosis Therapeutics Market Forecast
      • 10.4.5 Russia Cystic Fibrosis Therapeutics Market Forecast
    • 10.5 Middle East & Africa Cystic Fibrosis Therapeutics Forecast by Region (2025-2030)
      • 10.5.1 Egypt Cystic Fibrosis Therapeutics Market Forecast
      • 10.5.2 South Africa Cystic Fibrosis Therapeutics Market Forecast
      • 10.5.3 Israel Cystic Fibrosis Therapeutics Market Forecast
      • 10.5.4 Turkey Cystic Fibrosis Therapeutics Market Forecast
      • 10.5.5 GCC Countries Cystic Fibrosis Therapeutics Market Forecast
    • 10.6 Global Cystic Fibrosis Therapeutics Forecast by Type (2025-2030)
    • 10.7 Global Cystic Fibrosis Therapeutics Forecast by Application (2025-2030)
  • 11 Key Players Analysis

    • 11.1 Vertex Pharmaceuticals
      • 11.1.1 Vertex Pharmaceuticals Company Information
      • 11.1.2 Vertex Pharmaceuticals Cystic Fibrosis Therapeutics Product Offered
      • 11.1.3 Vertex Pharmaceuticals Cystic Fibrosis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.1.4 Vertex Pharmaceuticals Main Business Overview
      • 11.1.5 Vertex Pharmaceuticals Latest Developments
    • 11.2 F. Hoffmann-La Roche
      • 11.2.1 F. Hoffmann-La Roche Company Information
      • 11.2.2 F. Hoffmann-La Roche Cystic Fibrosis Therapeutics Product Offered
      • 11.2.3 F. Hoffmann-La Roche Cystic Fibrosis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.2.4 F. Hoffmann-La Roche Main Business Overview
      • 11.2.5 F. Hoffmann-La Roche Latest Developments
    • 11.3 AbbVie
      • 11.3.1 AbbVie Company Information
      • 11.3.2 AbbVie Cystic Fibrosis Therapeutics Product Offered
      • 11.3.3 AbbVie Cystic Fibrosis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.3.4 AbbVie Main Business Overview
      • 11.3.5 AbbVie Latest Developments
    • 11.4 Gilead Sciences
      • 11.4.1 Gilead Sciences Company Information
      • 11.4.2 Gilead Sciences Cystic Fibrosis Therapeutics Product Offered
      • 11.4.3 Gilead Sciences Cystic Fibrosis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.4.4 Gilead Sciences Main Business Overview
      • 11.4.5 Gilead Sciences Latest Developments
    • 11.5 Novartis
      • 11.5.1 Novartis Company Information
      • 11.5.2 Novartis Cystic Fibrosis Therapeutics Product Offered
      • 11.5.3 Novartis Cystic Fibrosis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.5.4 Novartis Main Business Overview
      • 11.5.5 Novartis Latest Developments
    • 11.6 AstraZeneca
      • 11.6.1 AstraZeneca Company Information
      • 11.6.2 AstraZeneca Cystic Fibrosis Therapeutics Product Offered
      • 11.6.3 AstraZeneca Cystic Fibrosis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.6.4 AstraZeneca Main Business Overview
      • 11.6.5 AstraZeneca Latest Developments
    • 11.7 Bayer
      • 11.7.1 Bayer Company Information
      • 11.7.2 Bayer Cystic Fibrosis Therapeutics Product Offered
      • 11.7.3 Bayer Cystic Fibrosis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.7.4 Bayer Main Business Overview
      • 11.7.5 Bayer Latest Developments
    • 11.8 Celtaxsys
      • 11.8.1 Celtaxsys Company Information
      • 11.8.2 Celtaxsys Cystic Fibrosis Therapeutics Product Offered
      • 11.8.3 Celtaxsys Cystic Fibrosis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.8.4 Celtaxsys Main Business Overview
      • 11.8.5 Celtaxsys Latest Developments
    • 11.9 Pharmaxis
      • 11.9.1 Pharmaxis Company Information
      • 11.9.2 Pharmaxis Cystic Fibrosis Therapeutics Product Offered
      • 11.9.3 Pharmaxis Cystic Fibrosis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.9.4 Pharmaxis Main Business Overview
      • 11.9.5 Pharmaxis Latest Developments
    • 11.10 ProQR Therapeutics
      • 11.10.1 ProQR Therapeutics Company Information
      • 11.10.2 ProQR Therapeutics Cystic Fibrosis Therapeutics Product Offered
      • 11.10.3 ProQR Therapeutics Cystic Fibrosis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.10.4 ProQR Therapeutics Main Business Overview
      • 11.10.5 ProQR Therapeutics Latest Developments
    • 11.11 PTC Therapeutics
      • 11.11.1 PTC Therapeutics Company Information
      • 11.11.2 PTC Therapeutics Cystic Fibrosis Therapeutics Product Offered
      • 11.11.3 PTC Therapeutics Cystic Fibrosis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.11.4 PTC Therapeutics Main Business Overview
      • 11.11.5 PTC Therapeutics Latest Developments
    • 11.12 Alcresta Therapeutics
      • 11.12.1 Alcresta Therapeutics Company Information
      • 11.12.2 Alcresta Therapeutics Cystic Fibrosis Therapeutics Product Offered
      • 11.12.3 Alcresta Therapeutics Cystic Fibrosis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.12.4 Alcresta Therapeutics Main Business Overview
      • 11.12.5 Alcresta Therapeutics Latest Developments
    • 11.13 Insmed Incorporated
      • 11.13.1 Insmed Incorporated Company Information
      • 11.13.2 Insmed Incorporated Cystic Fibrosis Therapeutics Product Offered
      • 11.13.3 Insmed Incorporated Cystic Fibrosis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.13.4 Insmed Incorporated Main Business Overview
      • 11.13.5 Insmed Incorporated Latest Developments
    • 11.14 Savara
      • 11.14.1 Savara Company Information
      • 11.14.2 Savara Cystic Fibrosis Therapeutics Product Offered
      • 11.14.3 Savara Cystic Fibrosis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.14.4 Savara Main Business Overview
      • 11.14.5 Savara Latest Developments
    • 11.15 Cyclacel Pharmaceuticals
      • 11.15.1 Cyclacel Pharmaceuticals Company Information
      • 11.15.2 Cyclacel Pharmaceuticals Cystic Fibrosis Therapeutics Product Offered
      • 11.15.3 Cyclacel Pharmaceuticals Cystic Fibrosis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.15.4 Cyclacel Pharmaceuticals Main Business Overview
      • 11.15.5 Cyclacel Pharmaceuticals Latest Developments
    • 11.16 Vectura
      • 11.16.1 Vectura Company Information
      • 11.16.2 Vectura Cystic Fibrosis Therapeutics Product Offered
      • 11.16.3 Vectura Cystic Fibrosis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.16.4 Vectura Main Business Overview
      • 11.16.5 Vectura Latest Developments
    • 11.17 Allergan
      • 11.17.1 Allergan Company Information
      • 11.17.2 Allergan Cystic Fibrosis Therapeutics Product Offered
      • 11.17.3 Allergan Cystic Fibrosis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
      • 11.17.4 Allergan Main Business Overview
      • 11.17.5 Allergan Latest Developments
  • 12 Research Findings and Conclusion

USD 3,660 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.
Global Cystic Fibrosis Therapeutics Market Growth (Status and Outlook) 2024-2030 | Pharmaceutical_LifeSciense Market Research Report - ShareFair Markets